Positives

• Health Rising covers a JAK inhibitor case in ME/CFS where Rinvoq calmed cytokine storm activity, with researchers proposing STAT inhibitors like ruxolitinib be trialed in Long COVID populations Health Rising.
  
  
• In the RuxCoFlam trial of COVID-triggered hyperinflammation, 71% of patients achieved a meaningful reduction in inflammation score by day 7 with low-grade reversible adverse events PMC.
  
  

Negatives

• In the broader RUXCOVID phase 3 study, ruxolitinib 5 mg twice daily showed no benefit in the overall hospitalized population and the primary endpoint was not met ScienceDirect.
  
  

Hurdles & Side Effects

• Ruxolitinib (Jakafi) is a specialty JAK1/2 inhibitor priced at thousands of dollars per month and typically restricted to myelofibrosis or polycythemia vera, making off-label Long COVID prescriptions extremely difficult to obtain Health Rising.